|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002871,
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0014822,
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0086418,
umls-concept:C0280100,
umls-concept:C0679729,
umls-concept:C1514162,
umls-concept:C1518578,
umls-concept:C1708528,
umls-concept:C1709323
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-2-4
|
|
pubmed:abstractText |
Platinum compounds are commonly associated with significant anemia. Erythropoietin administration has been found effective in correcting anemia in patients with solid tumors receiving chemotherapy. We conducted a randomized, open label study to assess the efficacy of erythropoietin in preventing transfusions and significant anemia (hemoglobin <10 g/dl) in patients with solid tumors receiving platinum-based chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
pubmed-author:AravantinosGG,
pubmed-author:BamiasAA,
pubmed-author:FountzilasGG,
pubmed-author:Hellenic Cooperative Oncology Group,
pubmed-author:JaninisDD,
pubmed-author:KalofonosCC,
pubmed-author:PavlidisNN,
pubmed-author:PectasidesDD,
pubmed-author:SiafakaVV,
pubmed-author:TimotheadouNN,
pubmed-author:VlahovNN
|
|
pubmed:copyrightInfo |
Copyright 2003 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
102-10
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12566906-Adult,
pubmed-meshheading:12566906-Aged,
pubmed-meshheading:12566906-Aged, 80 and over,
pubmed-meshheading:12566906-Anemia, Hypochromic,
pubmed-meshheading:12566906-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12566906-Blood Transfusion,
pubmed-meshheading:12566906-Erythropoietin,
pubmed-meshheading:12566906-Female,
pubmed-meshheading:12566906-Greece,
pubmed-meshheading:12566906-Humans,
pubmed-meshheading:12566906-Male,
pubmed-meshheading:12566906-Middle Aged,
pubmed-meshheading:12566906-Neoplasms,
pubmed-meshheading:12566906-Organoplatinum Compounds,
pubmed-meshheading:12566906-Prognosis,
pubmed-meshheading:12566906-Prospective Studies,
pubmed-meshheading:12566906-Quality of Life,
pubmed-meshheading:12566906-Recombinant Proteins,
pubmed-meshheading:12566906-Risk Factors,
pubmed-meshheading:12566906-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.
|
|
pubmed:affiliation |
Oncology Department, Ioannina University Hospital, Ioannina, Greece. abamias@med.uoa.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
